TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02064010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102
Description: Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102
Description: Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, administered orally for 4 weeks
Study: NCT01424423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion
Study: NCT01867463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel
Description: The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel
Description: The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
Study: NCT01424423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V. Infusion
Study: NCT06083506

Intervention type: DEVICE
Group type: OTHER
Intervention: NOVALOC TiN retained maxillary overdenture
Description: 4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
Study: NCT01148511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab was supplied as a sterile solution in sealed glass vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab was supplied as a sterile solution in sealed glass vials.
Study: NCT00860782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Educational Support
Description: Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Educational Support
Description: Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
Study: NCT01544751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose metformin
Description: 500 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day
Study: NCT02474108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical prevention of atrial fibrillation
Description: Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cardiomonitor
Description: in both groups cardiac rhythm will be controlled by a cardiomonitor

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cardiomonitor
Description: in both groups cardiac rhythm will be controlled by a cardiomonitor
Study: NCT02242708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative nostril breathing
Description: The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
Study: NCT02466555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
Study: NCT00763165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan
Description: Brush twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study: NCT02690610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS TBNA of mediastinal lesions or lymph nodes
Description: Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
Study: NCT00395850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
Study: NCT04790292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group M
Description: 10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group MD
Description: 10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
Study: NCT00804934

Intervention type: DRUG
Intervention: Lucentis
Description: 0.5mg Lucentis every four months
Study: NCT03973762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DR Grading with CAD
Description: A CAD system is used to make DR grading.

Intervention type: OTHER
Group type: OTHER
Intervention: DR Grading by expert panel
Description: DR Grading by expert panel
Study: NCT01177566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus
Description: pimecrolimus 1% cream twice daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical medical device
Description: Eletone cream three times daily
Study: NCT01867463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B
Description: Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B
Description: Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
Study: NCT03424174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation coated Total Knee Arthroplasty
Study: NCT04028518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-PA
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-PA
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.
Study: NCT03424174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation StandardTotal Knee Arthroplasty
Study: NCT03642717

Intervention type: DRUG
Intervention: JARDIANCE DUO®
Description: empagliflozin and metformin
Study: NCT04028518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase for Injection
Description: Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h.
Study: NCT02536534

Intervention type: OTHER
Intervention: Correlation assessment
Study: NCT00274287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM CSF
Description: 250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
Study: NCT04964037

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04117659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients
Description: discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
Study: NCT01789593

Intervention type: OTHER
Group type: OTHER
Intervention: glucose clamp
Description: Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test

Intervention type: OTHER
Group type: OTHER
Intervention: glucose clamp
Description: Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
Study: NCT04432909

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
Study: NCT01274000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral
Study: NCT00642668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
Study: NCT03387163

Intervention type: DRUG
Intervention: Sacubitril/Valsartan
Description: commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
Study: NCT00256698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg loading dose (LD) regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg oral tablet
Study: NCT03745092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: normobaric oxygen
Description: Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: room air
Description: The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
Study: NCT04255355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic alignment and forceful expiration
Description: The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic repositioning exercise
Description: The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise
Description: For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
Study: NCT00945581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Nutritional Powder Formula
Description: Powder twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Powder twice a day
Study: NCT02576028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM)
Description: Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard active exercises
Description: two sessions of 45 minutes of active exercises

Intervention type: OTHER
Group type: OTHER
Intervention: standard active exercises
Description: two sessions of 45 minutes of active exercises
Study: NCT03465332

Intervention type: OTHER
Intervention: Doctor's questionnaire
Description: The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.

Intervention type: OTHER
Intervention: Subject file
Description: All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
Study: NCT02620514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Reminders
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Visit
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
Study: NCT03311347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: +Gz accelerations and positive pressure breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: +Gz accelerations and positive pressure breathing
Study: NCT02445066

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D3
Study: NCT01274000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT02206607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 IR MST
Description: Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
Study: NCT02620514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Educational Visit
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Support
Description: Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
Study: NCT00713336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD4054
Description: ZD4054 10mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10mg Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZD4054
Description: ZD4054 10mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD4054 Placebo
Description: 3 tablets
Study: NCT02206607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 1
Description: Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 2
Description: Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 MR 3
Description: Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
Study: NCT03424187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chickpea
Description: all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chickpea
Description: all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chickpea
Description: all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea